جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

11 مُخرَج نتائج البحث عن «Atrial fibrillation»

مراجعةوصول مفتوح2026

Efficacy and Safety of Vernakalant for Cardioversion of Atrial Fibrillation and Flutter: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine · مجلد 15 (19) · 7406-7406

Background/Objectives: Vernakalant is an atrial-selective antiarrhythmic used for rapid pharmacological cardioversion of recent-onset atrial fibrillation. This systematic review and meta-analysis evaluated the efficacy and safety of vernakalant compared with placebo, active antiarrhythmic therapy, and electrical cardioversion. Methods: PubMed, Embase, Google Scholar, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to August 2026. Randomized clinical trials, clinical trials, and comparative observational studies evaluating vernakalant in adults with atrial fibrillation or atrial flutter were included. Dichotomous outcomes were pooled as risk ratios (RRs) with 95% confidence intervals (CIs) using the Mantel–Haenszel random-effects model in RevMan 5.4. Results: Twenty controlled studies involving 4523 patients were included, of whom 2349 received vernakalant and 2174 received control therapy. Vernakalant significantly increased successful conversion to sinus rhythm compared with all controls (1234/2244 (55%) vs. 991/2147 (46.2%); RR = 1.63; 95% CI [1.34, 1.99]; p < 0.00001). The effect was strongest versus placebo (RR = 5.33; 95% CI [1.95, 14.60]; p = 0.001) and remained significant versus procainamide (111/178 (62.3%) vs. 83/172 (48.2%); RR = 1.29; 95% CI [1.07, 1.57]; p = 0.009) and flecainide (209/280 vs. 209/330 (63.3%); RR = 1.18; 95% CI [1.05, 1.33]; p = 0.007), but non-significant against amiodarone, propafenone, ibutilide, or electrical cardioversion. Safety outcomes did not differ significantly between groups, including all-cause mortality (RR = 1.23), drug discontinuation (RR = 0.98), serious adverse events (RR = 0.87), ventricular tachycardia (RR = 0.68), bradycardia (RR = 1.31), and hypotension (RR = 0.80). Conclusions: Vernakalant was associated with higher rates of conversion to sinus rhythm, while no statistically significant differences were observed in major safety outcomes. These findings support its use as a pharmacological option for rapid rhythm restoration in appropriately selected patients.

vernakalantatrial fibrillationatrial flutterpharmacological cardioversion
مراجعةوصول مفتوح2026

Pulsed field ablation versus cryoballoon ablation for pulmonary vein isolation in atrial fibrillation: a systematic review and meta-analysis with subgroup analyses by AF type

BMC Cardiovascular Disorders · مجلد 26 (1)

BACKGROUND: Pulsed field ablation (PFA) is a non-thermal alternative to cryoballoon ablation (CBA) for pulmonary vein isolation in atrial fibrillation (AF). We compared their procedural efficiency, safety, and 1-year outcomes. METHODS: We searched PubMed, Scopus, Web of Science, CENTRAL, and Embase through October 2025 for randomized and comparative cohort studies of adults undergoing PFA or CBA. Outcomes were procedure duration, fluoroscopy time, left-atrial dwell time, periprocedural complications, and 1-year atrial arrhythmia recurrence, synthesized using random-effects meta-analyses with AF-type subgroup analyses. RESULTS: Twenty-three studies were included overall, of which 22 contributed to the quantitative synthesis. Overall, PFA shortened procedure duration versus CBA (mean difference [MD] − 11.50 min, 95% confidence interval [CI] − 15.39 to − 7.62), driven by persistent and mixed AF subgroups, while no significant difference was observed in paroxysmal AF. LA dwell time was reduced with PFA in paroxysmal AF, whereas fluoroscopy time did not differ significantly overall. Stroke, bleeding, and cardiac tamponade were comparable. PFA markedly decreased persistent (risk ratio [RR] 0.31, 95% CI 0.10–0.91) and transient (RR 0.19, 95% CI 0.07–0.53) phrenic nerve palsy. At 1 year, overall pooled analyses showed lower total atrial arrhythmia recurrence (RR 0.79, 95% CI 0.66–0.94) and AF recurrence (RR 0.72, 95% CI 0.62–0.83), with no difference in atrial flutter recurrence. CONCLUSIONS: PFA appears to offer shorter procedures and a more favorable phrenic-nerve safety profile than cryoballoon ablation, without evidence of excess major complications. Apparent 1-year efficacy advantages should be interpreted cautiously because the evidence base is dominated by observational studies and direct randomized PFA-versus-cryoballoon evidence remains limited.

pulsed field ablationcryoballoon ablationpulmonary vein isolationatrial fibrillation
مقالوصول مغلق2026

Trends in Cardiomyopathy and Atrial Fibrillation-Related Mortality Among US Adults, 1999–2024

Population Health Management · مجلد 29 (4) · 233-241

Atrial fibrillation (AF) is a highly prevalent comorbidity in patients with cardiomyopathy (CM), associated with worse cardiovascular outcomes. This study aims to provide a comprehensive, national-level analysis of AF and CM-related mortality in the United States. The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was utilized, using death certificates from 1999 to 2024. The study included patients aged ≥15 years with CM and AF. Statistical analyses were conducted to calculate age-adjusted mortality rates (AAMRs) per 100,000 individuals and annual percent changes with 95% confidence intervals (CIs). Between 1999 and 2024, CM with concomitant AF accounted for 134,470 deaths among individuals aged 15 years or older. The overall AAMR rose from 1.5 per 100,000 in 1999 to 2.3 in 2024. From 1999 to 2016, the AAMR rose modestly (1.5-1.8), followed by a pronounced rise from 2016 to 2022 (1.8-2.5), and a relative decline by 2024 (2.5-2.3). Compared with 2019, mortality in 2020 demonstrated a 15% relative increase (incidence rate ratio = 1.15; 95% CI: 1.11-1.19). Males had disproportionately higher AAMRs compared to females. By race, the highest AAMRs were observed in non-Hispanic (NH) Black and White populations (1.8 each). Regionally, the West and Midwest exhibited the highest AAMRs (1.9 each). Urban-rural stratification revealed higher AAMRs among rural areas (2.2) when compared with urban (1.8) areas. Targeted public-health interventions and resource allocation to address this growing cardiovascular mortality burden, particularly in high-risk demographic groups, are needed.

cardiomyopathyatrial fibrillationmortality trendscomorbidities
مقالوصول مغلق2025

Trends in pulmonary embolism and atrial fibrillation-related mortality in adult US population: a CDC WONDER analysis from 1999 to 2020

European Heart Journal · مجلد 46 (Supplement_1)

Abstract Background Pulmonary embolism (PE) continues to be a major contributor to mortality in the United States. Among the various risk factors associated with this life-threatening condition, atrial fibrillation (AF) stands as a significant contributor, further complicating the health challenges faced by patients. Purpose This study aims to uncover critical trends and regional disparities in mortality related to PE with concomitant AF across the United States from 1999 to 2020. Methods Death certificate data from the Centers for Disease Control and Prevention Wide-Ranging OnLine Data for Epidemiologic Research (CDC WONDER) database was to evaluate mortality associated with pulmonary embolism (PE) and atrial fibrillation/flutter (AF) from 1999 to 2020 for adults >15 years. Age-adjusted mortality rates (AAMRs) per 100,000 individuals, and Annual Percent Change (APCs) along with their 95% confidence intervals (CIs) were also calculated. Data were stratified by year, sex, race, and census region. Results PE with comorbid AF in adults aged ≥ 15 years resulted in 38,848 deaths, with an overall AAMR 0.70 (APC - 4.45; 95% CI: 3.94 – 4.96). The AAMR increased from 0.4 in 1999 to 0.8 in 2018 (APC: 4.2; 95% CI: 3.6 to 4.8), and further increased to 1.1 in 2020 (APC: 11.97; 95% CI: -7.3 – 35.2). Similar AAMR values were reported in both male and female in 1999 (AAMR: 0.4), however, men showed a slightly higher increase by 2020 (AAMR men: 1.4 vs women: 1.0). Non-Hispanic (NH) White adults had the highest overall AAMR (0.7), followed by NH Black (0.6), NH American Indian/Alaska Native (0.4), Hispanic or Latino (0.3), and NH Asian or Pacific Islander adults (0.2). AAMR did not vary substantially by region (overall AAMR: Midwest 0.7; South: 0.7; West: 0.7; Northeast: 0.6), and metropolitan areas had higher PE with comorbid AF-related AAMR (1.0) than nonmetropolitan areas (0.8). Wyoming, Colorado, and Vermont ranked in the top 90th percentile for PE with comorbid AF-related AAMR, with rates nearly four times higher than states in the lowest 10th percentile. Conclusion There’s been a steady increase in PE mortality with comorbid AF over the last 20 years. AAMR values were greater among non-Hispanic Adults, and those residing in metropolitan areas of the US. Notably, a sharper rise in AAMR post-2018 has been reported in both males and females. These findings highlight the importance of addressing and developing targeted interventions to curb the increased PE with comorbid AF mortality rates in the vulnerable population.

pulmonary embolismatrial fibrillationatrial fluttermortality trends
مقالوصول مفتوح20231استشهاد· Semantic Scholar

Real-world Experience in Managing Atrial Fibrillation in Patients with Renal Impairment; Rivaroxaban versus Warfarin

Heart Views · مجلد 24 (3) · 136-140

Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment. Methods: This retrospective study was conducted between 2015 and 2016 to compare the use of warfarin ( n = 164) and rivaroxaban ( n = 149) in patients with AF and moderate or severe CKD. The study outcomes were survival, stroke, and major bleeding events. The median follow-up was 50 months (interquartile range: 23–60). Results: Thirty-six patients had major bleeding: 24 with rivaroxaban and 12 with warfarin ( P = 0.01). The rivaroxaban group had major bleeding in 3 patients with moderate CKD, 4 with severe CKD, and 17 on dialysis. Multivariable analysis of factors affecting major bleeding revealed that warfarin use lowered the risk of bleeding (hazard ratio: 0.34; P = 0.004). Stroke occurred in 14 patients: 6 in the rivaroxaban group and 8 in the warfarin group ( P = 0.44). Survival at 1, 3, and 5 years was 89%, 77%, and 71% with warfarin and 99%, 94%, and 88% with rivaroxaban, respectively ( P < 0.001). Multivariable analysis showed higher mortality in patients with lower creatinine clearance and those on warfarin. Conclusions: The safety of warfarin could be better than rivaroxaban in patients with CKD with fewer bleeding complications but similar stroke rates. Further studies on rivaroxaban dosing in patients on dialysis are required.

atrial fibrillationchronic kidney diseaserenal dysfunctionrivaroxaban
مقالوصول مفتوح2023

Better survival in morbidly obese patients with atrial fibrillation treated with non-vitamin K-dependent oral anticoagulants

Journal of the Saudi Heart Association · مجلد 35 (1) · 7-15

Background: The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are not well investigated in the obese population, and fixed dosing could lead to under-anticoagulation. Our objective was to evaluate the effect of obesity on anticoagulation outcomes and survival in non-valvular atrial fibrillation (AF) patients. Methods: We enrolled 755 patients who required anticoagulation for AF from 2015 to 2016. We grouped the patients into four groups. Group 1 (n = 297) included patients with BMI< 40 kg/m2 treated with NOACs, Group 2 (n = 358) included patients on warfarin with BMI< 40 kg/m2, Group 3 (n = 57) had patients on NOACs with BMI≥ 40 kg/m2 and Group 4 (n = 43) included patients on warfarin and BMI≥ 40 kg/m2. Study outcomes were the composite endpoint of stroke, bleeding, and survival. Results: Competing risk regression showed that stroke and bleeding were not affected by obesity or treatment (SHR: 1.09 (95% CI: 0.79-1.51); P = 0.62). Older age was the predictor of stroke/bleeding (HR:1.03 (95% CI:1.01-1.06); P = 0.02). Predictors of mortality were heart failure (HR:2.23 (95% CI:1.25-3.97); P = 0.007), lower creatinine clearance (HR: 0.98 (95% CI:0.97-0.98): P < 0.001), non-obese patients on warfarin (HR:3.51 (95%CI:1.6-7.7): P = 0.002) and obese patients on warfarin (HR: 6.7 (95% CI:2.51-17.92); P < 0.001). Conclusion: NOACs could have a similar risk profile to warfarin in obese and non-obese patients with non-valvular AF but could have better survival. Larger randomized trials are recommended.

morbid obesitynon-valvular atrial fibrillationwarfarinsurvival
مقالوصول مفتوح202211استشهاد· Semantic Scholar

Predictors and clinical outcomes of post-coronary artery bypass grafting cerebrovascular strokes

The Egyptian Heart Journal · مجلد 74 (1) · 76-76

BACKGROUND: Despite the improved medical and surgical managements, still there is a significant risk of developing acute cerebrovascular strokes after coronary artery bypass grafting (CABG). Our objectives were to study the immediate and long-term outcomes after CABG and to identify the possible predictors of post-CABG strokes. RESULTS: Between January 2016 and August 2020, 410 adult patients, mostly males (82.2%), were retrospectively enrolled after CABG. Acute postoperative strokes occurred in 31 (7.5%) patients; of them, 30 (96.8%) patients had ischemic stroke, while 1 (3.2%) had hemorrhagic stroke. Mechanical thrombectomy was done in two cases. The patients who developed acute cerebral stroke had significantly higher admission (p = 0.02) and follow-up (p < 0.001) SOFA scores, higher arterial blood lactate level (p < 0.001), longer hospitalization (p < 0.001) and more hospital mortality (p < 0.001) compared with the patients who did not develop stroke. Kaplan-Meier curves for 5-year mortality showed increased risk in those patients with postoperative stroke (HR: 23.03; 95% CI: 6.10-86.92, p < 0.001). After multivariate regression, the predictors of early postoperative stroke were carotid artery stenosis (CAS), postoperative atrial fibrillation, cardiopulmonary bypass time, prior cerebral stroke, admission SOFA score and chronic kidney disease (CKD). The predictors of late cerebrovascular stroke were CAS, combined CABG and valve surgery, CKD, atrial fibrillation, prior stroke and HbA1c. CONCLUSIONS: The development of post-CABG acute cerebrovascular stroke is associated with longer hospitalization, multiple morbidities and increased mortality. Careful assessment and management of risk factors especially atrial fibrillation and carotid artery stenosis should be implemented to decrease this substantial complication after CABG.

postoperative strokecoronary artery bypass graftingischemic strokehemorrhagic stroke
مقالمفتوح (مستودع)2022

Clinical outcomes and predictors of acute cerebrovascular strokes after coronary artery bypass graft surgery

European Heart Journal Acute Cardiovascular Care · مجلد 11 (Supplement_1)

Abstract Funding Acknowledgements Type of funding sources: None. Background Coronary artery bypass graft (CABG) surgery still carries a significant risk acute cerebrovascular stroke despite advances in anesthetic, surgical and medical managements. Objective To study the risk factors and get the predictors of acute stroke after CABG and study the clinical outcomes during hospitalization and follow up. Methods This retrospective study included 410 patients who underwent CABG at our tertiary care hospital from January 2016 to August 2020. The patients were divided into two groups according to the occurrence of acute cerebrovascular stroke. Results The study included 410 patients with a median age of 60(55-68) years with a male predominance (82.2%). Thirty-one (7.5%) patients developed strokes after CABG. The stroke group had significantly higher initial sequential organ failure assessment (SOFA) score [ 3(2-4) vs. 2(1-3), p=0.002], SOFA after 48 hours [5(1-7) vs. 1(0-2), p<0.001], higher peak blood lactate level [12.5(7.6-14.7) vs. 5.1(3.7-8.5),p<0.001], longer ICU stay [11(6-42) vs. 4(3-5), p<0.001], more ventilator days [10(2-32) vs. 1(1-2), p<0.001], more tracheostomies (38.7 vs. 0, p<0.001) ,longer post ICU ward stay [11(2-57) vs. 5(3-7), p=0.015] and greater hospital mortality (25.8 vs. 0.8, p<0.001) compared to the non-stroke group respectively. Both groups showed insignificant mortality during a follow up period of 41.5(26.5-54.5) months. Multivariate regression revealed that early hospital stroke was independently predicted with carotid artery disease (OR:8.22, 95%CI:2.92-23.1, p<0.001), CPB time (OR:5.64, 95%CI:1.97-16.11, p<0.001), initial SOFA score (OR:1.643, 95%CI:1.194-2.26, p=0.002), prior stroke (OR:4.412, 95%CI:1.286-15.14, p=0.018), postoperative new AF (OR: 3.014, 95%CI:1.158-7.84, p=0.024) and CKD (OR:1.28,95%CI:1.05-3.75, p=0.017). Late cerebrovascular stroke was independently predicted with CAD (OR:9.38, 95%CI:3.72-23.66, p<0.001), postoperative AF (OR: 2.35,95%CI:1.0125-5.41, p=0.016), prior stroke (OR:3.725,95%CI:1.179-11.768, p=0.025), CABG plus valve surgery (0R:7.44, 95%CI:2.75-20.145, p<0.001), HBA1c (OR:1.431, 95%CI:1.071-1.914, p=0.016) and CKD (OR:2.33, 95%CI:1.056-5.165, p=0.036). Conclusion Acute cerebrovascular stroke is a serious complication after CABG and associated with increased mortality, longer hospital stays with multiple morbidities and resources consumption. Appropriate assessment and management of carotid artery disease, and post-operative atrial fibrillation should be routinely implemented to reduce the risk of early and late strokes in patients undergoing CABG.

strokecoronary artery bypass graftingpostoperative strokerisk factors
مقالمفتوح (مستودع)2022

Screening, Prevention and Risk Factors of Stroke in Adult Patients

Journal of Healthcare Sciences · مجلد 02 (04) · 46-51

Stroke, also known as a cerebrovascular accident, is a medical emergency characterized by an immediate disruption of cerebral perfusion or vasculature. Strokes are divided into two categories: ischemic stroke and haemorrhagic stroke. Strokes can be caused by a variety of factors, including high blood pressure, arteriosclerosis, and emboli generated in the heart as a consequence of atrial fibrillation or rheumatic heart disease. Stroke is linked to a number of risk factors, that are categorized into modifiable and non-modifiable risk factors. In order to reduce stroke-related morbidity and mortality, prevention is critical. It is believed that 50% of strokes can be avoided by controlling modifiable risk factors and making lifestyle modifications. The purpose of this research is to review the available information regarding screening, risk factors and prevention of stroke. Hypertension, smoking, obesity, diet, lack of physical activity, diabetes mellitus, alcohol consumption, mental distress, heart disease, and lipid disorders account for 90% of strokes, depending on the number of risk factors included. Medical interventions that have been demonstrated in numerous randomized trials can significantly lower the risk of stroke. Observational research clearly suggests that healthy eating habits, quitting smoking and abstaining from excessive alcohol consumption, regular physical activity, and maintaining a normal body weight are all helpful for stroke prevention. In order to facilitate services for preventative stroke treatments and acute stroke care, community awareness of stroke risk factors and symptoms must be improved. Education, awareness as well as screening for risk factors of stroke among public is need of time.

strokestroke risk factorsstroke preventionstroke screening
مقالوصول مفتوح202013استشهاد

Assessment of the quality of anticoagulation management with warfarin in a tertiary care center

Saudi Medical Journal · مجلد 41 (11) · 1245-1251

OBJECTIVES: To evaluate the quality of an anticoagulation clinic in a tertiary hospital and identified factors affecting the time in the therapeutic range (TTR) and its relation to different complications. Methods: This single-center retrospective study conducted between March 2015 and June 2016 included 1914 patients receiving warfarin therapy. They were divided into 4 warfarin indication groups: non-valvular atrial fibrillation (AF) (n=403), valvular AF (n=227), prosthetic valves (n=700), and venous or pulmonary embolism (n=584). RESULTS: The median age was 56 (25th, 75th percentiles: [45, 67]) years, and 53.2% were female. The median TTR was 0.52 (0.28, 0.76). Low hemoglobin (0.007) and high alkaline phosphatase (0.020) levels negatively affected the TTR. Venous thromboembolism (VTE) was associated with low TTRs. Minor bleeding occurred in 64 (3.35%), gastrointestinal bleeding in 14 (0.7%), and stroke in 41 (2.2%) patients, with no inter-group differences. The TTR was not associated with minor bleeding (odds ratio [OR]=0.49; p=0.09), gastrointestinal bleeding (OR=0.29; p=0.18), or stroke (OR=1.15; p=0.79). CONCLUSION: Reflecting the real-life experience of anticoagulation control, our patients spend less than half the TTR within the INR. The low target TTR mandates the need to improve service quality and control factors affecting the TTR, including hemoglobin levels and regular visits for patients with VTE.

warfarinanticoagulation managementtime in therapeutic rangenon-valvular atrial fibrillation